This concentration-dependent decrease in NF-kB expression points to the potential of Th-ZnNPs as a targeted therapeutic approach for glioblastoma, potentially enhancing treatment efficacy by disrupting key signaling pathways involved in tumor progression and resistance. The gene discussed is NFKB1; the disease is glioblastoma.